PURPOSE: Breast cancer stem-like cells (CSC) are an important therapeutic target as they are predicted to be responsible for tumor initiation, maintenance, and metastases. Interleukin (IL)-8 is upregulated in breast cancer and is associated with poor prognosis. Breast cancer cell line studies indicate that IL-8 via its cognate receptors, CXCR1 and CXCR2, is important in regulating breast CSC activity. We investigated the role of IL-8 in the regulation of CSC activity using patient-derived breast cancers and determined the potential benefit of combining CXCR1/2 inhibition with HER2-targeted therapy. EXPERIMENTAL DESIGN: CSC activity of metastatic and invasive human breast cancers (n = 19) was assessed ex vivo using the mammosphere colony-forming assay. RESULTS: Metastatic fluid IL-8 level correlated directly with mammosphere formation (r = 0.652; P < 0.05; n = 10). Recombinant IL-8 directly increased mammosphere formation/self-renewal in metastatic and invasive breast cancers (n = 17). IL-8 induced activation of EGFR/HER2 and downstream signaling pathways and effects were abrogated by inhibition of SRC, EGFR/HER2, phosphoinositide 3-kinase (PI3K), or MEK. Furthermore, lapatinib, which targets EGFR/HER2, inhibited the mammosphere-promoting effect of IL-8 in both HER2-positive and negative patient-derived cancers. CXCR1/2 inhibition also blocked the effect of IL-8 on mammosphere formation and added to the efficacy of lapatinib in HER2-positive cancers. CONCLUSIONS: These studies establish a role for IL-8 in the regulation of patient-derived breast CSC activity and show that IL-8/CXCR1/2 signaling is partly mediated via a novel SRC and EGFR/HER2-dependent pathway. Combining CXCR1/2 inhibitors with current HER2-targeted therapies has potential as an effective therapeutic strategy to reduce CSC activity in breast cancer and improve the survival of HER2-positive patients.
PURPOSE: Breast cancer stem-like cells (CSC) are an important therapeutic target as they are predicted to be responsible for tumor initiation, maintenance, and metastases. Interleukin (IL)-8 is upregulated in breast cancer and is associated with poor prognosis. Breast cancer cell line studies indicate that IL-8 via its cognate receptors, CXCR1 and CXCR2, is important in regulating breast CSC activity. We investigated the role of IL-8 in the regulation of CSC activity using patient-derived breast cancers and determined the potential benefit of combining CXCR1/2 inhibition with HER2-targeted therapy. EXPERIMENTAL DESIGN: CSC activity of metastatic and invasive human breast cancers (n = 19) was assessed ex vivo using the mammosphere colony-forming assay. RESULTS: Metastatic fluid IL-8 level correlated directly with mammosphere formation (r = 0.652; P < 0.05; n = 10). Recombinant IL-8 directly increased mammosphere formation/self-renewal in metastatic and invasive breast cancers (n = 17). IL-8 induced activation of EGFR/HER2 and downstream signaling pathways and effects were abrogated by inhibition of SRC, EGFR/HER2, phosphoinositide 3-kinase (PI3K), or MEK. Furthermore, lapatinib, which targets EGFR/HER2, inhibited the mammosphere-promoting effect of IL-8 in both HER2-positive and negative patient-derived cancers. CXCR1/2 inhibition also blocked the effect of IL-8 on mammosphere formation and added to the efficacy of lapatinib in HER2-positive cancers. CONCLUSIONS: These studies establish a role for IL-8 in the regulation of patient-derived breast CSC activity and show that IL-8/CXCR1/2 signaling is partly mediated via a novel SRC and EGFR/HER2-dependent pathway. Combining CXCR1/2 inhibitors with current HER2-targeted therapies has potential as an effective therapeutic strategy to reduce CSC activity in breast cancer and improve the survival of HER2-positive patients.
Authors: C C Benz; G K Scott; J C Sarup; R M Johnson; D Tripathy; E Coronado; H M Shepard; C K Osborne Journal: Breast Cancer Res Treat Date: 1992 Impact factor: 4.872
Authors: Jianhua Chao; Arthur G Taveras; Jianping Chao; Cynthia Aki; Michael Dwyer; Younong Yu; Biju Purakkattle; Diane Rindgen; James Jakway; William Hipkin; James Fosetta; Xuedong Fan; Daniel Lundell; Jay Fine; Michael Minnicozzi; Jonathan Phillips; J Robert Merritt Journal: Bioorg Med Chem Lett Date: 2007-04-10 Impact factor: 2.823
Authors: Hannah Harrison; Gillian Farnie; Sacha J Howell; Rebecca E Rock; Spyros Stylianou; Keith R Brennan; Nigel J Bundred; Robert B Clarke Journal: Cancer Res Date: 2010-01-12 Impact factor: 12.701
Authors: Masayuki Shimoda; Simona Principe; Hartland W Jackson; Valbona Luga; Hui Fang; Sam D Molyneux; Yang W Shao; Alison Aiken; Paul D Waterhouse; Christina Karamboulas; Franz M Hess; Takashi Ohtsuka; Yasunori Okada; Laurie Ailles; Andreas Ludwig; Jeffrey L Wrana; Thomas Kislinger; Rama Khokha Journal: Nat Cell Biol Date: 2014-08-24 Impact factor: 28.824
Authors: C Visciano; F Liotti; N Prevete; G Cali'; R Franco; F Collina; A de Paulis; G Marone; M Santoro; R M Melillo Journal: Oncogene Date: 2015-01-26 Impact factor: 9.867
Authors: Kelly E Johnson; Julia R Ceglowski; Harvey G Roweth; Jodi A Forward; Mason D Tippy; Saleh El-Husayni; Rajesh Kulenthirarajan; Michael W Malloy; Kellie R Machlus; Wendy Y Chen; Joseph E Italiano; Elisabeth M Battinelli Journal: Blood Adv Date: 2019-01-22